Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
复制标题
DOI：
10.1002/alz.12556
复制
发表时间：
2022-05
影响因子：
14
通讯作者：
Wisniewski, Thomas
中科院分区：
文献类型：
--
作者：
Frontera, Jennifer A.;Boutajangout, Allal;Masurkar, Arjun, V;Betensky, Rebecca A.;Ge, Yulin;Vedvyas, Alok;Debure, Ludovic;Moreira, Andre;Lewis, Ariane;Huang, Joshua;Thawani, Sujata;Balcer, Laura;Galetta, Steven;Wisniewski, Thomas
关键词：
住院COVID-19患者的神经系统并发症可能与神经退行性生物标志物升高有关。在没有痴呆病史的住院COVID-19患者（N = 251）中，我们比较了血清总tau蛋白（t-tau）、磷酸化tau-181（p‐ tau 181）、胶质细胞酸性蛋白（GFAP）、神经丝轻链（NfL）、泛素羧基末端水解酶L1（UCHL 1）和β淀粉样蛋白（Aβ 40，42）在有或无脑病患者之间的差异，住院死亡与生存，出院回家而不是其他处置还将COVID-19患者的生物标志物水平与非COVID认知正常、轻度认知障碍（MCI）和阿尔茨海默病（AD）痴呆对照（N = 161）进行了比较。在脑病患者和在医院死亡的患者中，入院时t-tau、p-tau 181、GFAP和NfL显著升高，而出院回家的患者中t-tau、GFAP和NfL显著降低。这些标志物与COVID疾病的严重程度相关。COVID患者的NfL、GFAP和UCHL 1高于非COVID对照MCI或AD患者。神经退行性生物标志物升高至AD痴呆中观察到的水平，并与住院COVID-19患者的脑病和更差结局相关。
Neurological complications among hospitalized COVID‐19 patients may be associated with elevated neurodegenerative biomarkers. Among hospitalized COVID‐19 patients without a history of dementia (N = 251), we compared serum total tau (t‐tau), phosphorylated tau‐181 (p‐tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxy‐terminal hydrolase L1 (UCHL1), and amyloid beta (Aβ40,42) between patients with or without encephalopathy, in‐hospital death versus survival, and discharge home versus other dispositions. COVID‐19 patient biomarker levels were also compared to non‐COVID cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia controls (N = 161). Admission t‐tau, p‐tau181, GFAP, and NfL were significantly elevated in patients with encephalopathy and in those who died in‐hospital, while t‐tau, GFAP, and NfL were significantly lower in those discharged home. These markers correlated with severity of COVID illness. NfL, GFAP, and UCHL1 were higher in COVID patients than in non‐COVID controls with MCI or AD. Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID‐19 patients.
登录
查看更多内容
DOI：
10.1016/j.clinph.2021.03.016
发表时间：
2021-07
期刊：
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
影响因子：
--
作者：
Frithiof R;Rostami E;Kumlien E;Virhammar J;Fällmar D;Hultström M;Lipcsey M;Ashton N;Blennow K;Zetterberg H;Punga AR
通讯作者：
Punga AR
影响因子：
3.5
作者：
Frontera JA;Melmed K;Fang T;Granger A;Lin J;Yaghi S;Zhou T;Lewis A;Kurz S;Kahn DE;de Havenon A;Huang J;Czeisler BM;Lord A;Meropol SB;Troxel AB;Wisniewski T;Balcer L;Galetta S
通讯作者：
Galetta S
影响因子：
3.7
作者：
Ehler, Johannes;Petzold, Axel;Sauer, Martin
通讯作者：
Sauer, Martin
影响因子：
6
作者：
De Lorenzo R;Loré NI;Finardi A;Mandelli A;Cirillo DM;Tresoldi C;Benedetti F;Ciceri F;Rovere-Querini P;Comi G;Filippi M;Manfredi AA;Furlan R
通讯作者：
Furlan R
影响因子：
9.9
作者：
Frontera, Jennifer A.;Sabadia, Sakinah;Galetta, Steven
通讯作者：
Galetta, Steven